Endo International (NASDAQ: ENDP): Q4 2019 Earnings Snapshot

— Endo International plc (NASDAQ: ENDP) reported its fourth-quarter 2019 adjusted earnings of $0.74 per share versus $0.57 per share expected.

— Total revenues declined by 3% to $764.8 million versus $731.43 million expected. This was due to competitive pressures in the Generic Pharmaceuticals segment and the Established Products portfolio of the Branded Pharmaceuticals segment.

— Branded Pharmaceuticals revenues decreased by 2% due to the ongoing generic competition in the Established Products portfolio.

— Specialty Products revenues increased by 15% primarily driven by the continued strong performance of Xiaflex. The demand growth in both the Peyronie’s Disease and Dupuytren’s Contracture indications drove Xiaflex sales higher.

— Revenues of the Sterile Injectables segment increased by 10% to $285 million. This was driven by the continued strong growth of Vasostrict and Adrenalin.

— Generic Pharmaceuticals revenues dropped by 14% due to the continued competitive pressure on commoditized generic products. The ongoing generic competition also hurt the International Pharmaceuticals revenue, which fell by 16%.

— Looking ahead into the full year 2020, the company expects total revenue of $2.72-2.92 billion and adjusted EPS from continuing operations of $2.15-2.40. The consensus estimates EPS of $2.25 on revenue of $2.90 billion.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!